Scholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million. In the quarter to June 2026, EPS grew 14.3%, free cash flow grew 8.88% and total debt rose 294.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow SRRK
Scholar Rock Holding Corporation (SRRK) P/E ratio
Scholar Rock Holding Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2022 | 0.0× | — |
| Dec 2021 | 0.0× | — |
| Sep 2021 | 0.0× | — |
| Jun 2021 | 0.0× | — |
| 9 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| COGT Cogent Biosciences, Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | n/m |
| ORKA Oruka Therapeutics, Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| MIRM Mirum Pharmaceuticals, Inc. compare | n/m |
| TVTX Travere Therapeutics, Inc. compare | n/m |
| SRRK Scholar Rock Holding Corporation | n/m |
| DFTX Definium Therapeutics, Inc. compare | n/m |
| CRSP CRISPR Therapeutics AG compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)